GlobeImmune is Fierce!

Congratulations to GlobeImmune for being named to Fierce Biotech’s 2008 Fierce 15 List (click HERE for a link to see the other 15 companies)! What makes it Fierce: GlobeImmune's third round of financing last fall was its biggest, $41.2M, bringing its total venture haul to north of $88M. Wexford capital led the round and Celgene, Boston Life Science Venture, Morgenthaler Ventures and Biogen Idec all participated. The money takes the company to a crucial inflection point: Phase II data that determines if the company's platform technology can deliver the kind of T-cell response it is looking for. GlobeImmune has three mid-stage studies underway to determine if its genetically modified recombinant yeast can induce T-cells to attack pancreatic cancer and hepatitis C.

GlobeImmune has been developing Tarmogens (Targeted Molecular Immunogens) based on scientific research in-licensed from the University of Colorado. And its development programs in divergent areas like hep C and cancer underscores just how broad a range the company could have. One successful program could lead to several more. Enrollment for the hepatitis C Phase II was wrapped in May. The study for pancreatic cancer is underway and a Phase IIa in non-small cell lung cancer--enrolling patients with a ras mutation--was launched in March. A successful mid-stage trial sets the stage for broadening the company's research activities, is likely to excite new partnership interest and also moves the company one step closer to evaluating its worth in a potential IPO.

*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!

If you enjoyed this post get free email or RSS updates (here).